These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 7775863)

  • 21. Apolipoprotein E5 (Glu212-->Lys): increased binding to cell surface proteoglycans but decreased uptake and lysosomal degradation in cultured fibroblasts.
    Feussner G; Scharnagl H; Scherbaum C; Acar J; Dobmeyer J; Lohrmann J; Wieland H; März W
    J Lipid Res; 1996 Aug; 37(8):1632-45. PubMed ID: 8864947
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Opposing effects of apolipoproteins E and C on lipoprotein binding to low density lipoprotein receptor-related protein.
    Kowal RC; Herz J; Weisgraber KH; Mahley RW; Brown MS; Goldstein JL
    J Biol Chem; 1990 Jun; 265(18):10771-9. PubMed ID: 2355022
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Defective hepatic lipoprotein receptor binding of beta-very low density lipoproteins from type III hyperlipoproteinemic patients. Importance of apolipoprotein E.
    Hui DY; Innerarity TL; Mahley RW
    J Biol Chem; 1984 Jan; 259(2):860-9. PubMed ID: 6319389
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Defective VLDL metabolism and severe atherosclerosis in mice expressing human apolipoprotein E isoforms but lacking the LDL receptor.
    Knouff C; Briand O; Lestavel S; Clavey V; Altenburg M; Maeda N
    Biochim Biophys Acta; 2004 Aug; 1684(1-3):8-17. PubMed ID: 15450205
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Secretion-capture role for apolipoprotein E in remnant lipoprotein metabolism involving cell surface heparan sulfate proteoglycans.
    Ji ZS; Fazio S; Lee YL; Mahley RW
    J Biol Chem; 1994 Jan; 269(4):2764-72. PubMed ID: 8300609
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Human apolipoprotein E7:lysine mutations in the carboxy-terminal domain are directly responsible for preferential binding to very low density lipoproteins.
    Dong J; Balestra ME; Newhouse YM; Weisgraber KH
    J Lipid Res; 2000 Nov; 41(11):1783-9. PubMed ID: 11060347
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intravenous heparinase inhibits remnant lipoprotein clearance from the plasma and uptake by the liver: in vivo role of heparan sulfate proteoglycans.
    Ji ZS; Sanan DA; Mahley RW
    J Lipid Res; 1995 Mar; 36(3):583-92. PubMed ID: 7539827
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular mechanisms of type III hyperlipoproteinemia: The contribution of the carboxy-terminal domain of ApoE can account for the dyslipidemia that is associated with the E2/E2 phenotype.
    Kypreos KE; Li X; van Dijk KW; Havekes LM; Zannis VI
    Biochemistry; 2003 Aug; 42(33):9841-53. PubMed ID: 12924933
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Very-low-density lipoprotein binding to the apolipoprotein E receptor 2 is enhanced by lipoprotein lipase, and does not require apolipoprotein E.
    Tacken PJ; Beer FD; Vark LC; Havekes LM; Hofker MH; Willems Van Dijk K
    Biochem J; 2000 Apr; 347(Pt 2):357-61. PubMed ID: 10749663
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The significance of apolipoprotein E structure to the metabolism of plasma triglyceride-rich lipoproteins.
    Dergunov AD; Rosseneu M
    Biol Chem Hoppe Seyler; 1994 Aug; 375(8):485-95. PubMed ID: 7811390
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Familial dysbetalipoproteinemia: a genetically heterogenous disease caused by mutations of the ligand apolipoprotein E.
    Vermeer BJ; Frants RR; Havekes LM
    J Invest Dermatol; 1992 Jun; 98(6 Suppl):57S-60S. PubMed ID: 1588125
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of alpha 2M receptor/LRP in chylomicron remnant metabolism.
    Beisiegel U; Krapp A; Weber W; Olivecrona G
    Ann N Y Acad Sci; 1994 Sep; 737():53-69. PubMed ID: 7524435
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Apolipoprotein E mutations: a comparison between lipoprotein glomerulopathy and type III hyperlipoproteinemia.
    Matsunaga A; Saito T
    Clin Exp Nephrol; 2014 Apr; 18(2):220-4. PubMed ID: 24570178
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Apolipoprotein E and lipoprotein lipase secreted from human monocyte-derived macrophages modulate very low density lipoprotein uptake.
    Ishibashi S; Yamada N; Shimano H; Mori N; Mokuno H; Gotohda T; Kawakami M; Murase T; Takaku F
    J Biol Chem; 1990 Feb; 265(6):3040-7. PubMed ID: 2303437
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lipoproteins of special significance in atherosclerosis. Insights provided by studies of type III hyperlipoproteinemia.
    Mahley RW; Innerarity TL; Rall SC; Weisgraber KH
    Ann N Y Acad Sci; 1985; 454():209-21. PubMed ID: 3000263
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The composition, structural properties and binding of very-low-density and low-density lipoproteins to the LDL receptor in normo- and hypertriglyceridemia: relation to the apolipoprotein E phenotype.
    Dergunov AD; Novoselov AV; Visvikis S; Siest G; Yakushkin VV; Tsibulsky V
    Biol Chem; 2005 May; 386(5):441-52. PubMed ID: 15927888
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel mechanism for defective receptor binding of apolipoprotein E2 in type III hyperlipoproteinemia.
    Dong LM; Parkin S; Trakhanov SD; Rupp B; Simmons T; Arnold KS; Newhouse YM; Innerarity TL; Weisgraber KH
    Nat Struct Biol; 1996 Aug; 3(8):718-22. PubMed ID: 8756331
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preferential association of apolipoprotein E Leiden with very low density lipoproteins of human plasma.
    Fazio S; Horie Y; Weisgraber KH; Havekes LM; Rall SC
    J Lipid Res; 1993 Mar; 34(3):447-53. PubMed ID: 8468528
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Blockade of the alpha 2-macroglobulin receptor/low-density-lipoprotein-receptor-related protein on rat liver parenchymal cells by the 39-kDa receptor-associated protein leaves the interaction of beta-migrating very-low-density lipoprotein with the lipoprotein remnant receptor unaffected.
    Ziere GJ; van der Kaaden ME; Vogelezang CJ; Boers W; Bihain BE; Kuiper J; Kruijt JK; van Berkel TJ
    Eur J Biochem; 1996 Dec; 242(3):703-11. PubMed ID: 9022700
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of apolipoprotein C-I peptides on the apolipoprotein E content and receptor-binding properties of beta-migrating very low density lipoproteins.
    Swaney JB; Weisgraber KH
    J Lipid Res; 1994 Jan; 35(1):134-42. PubMed ID: 8138714
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.